日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ

EGFR激活通过SHP2介导的抑制肿瘤对IFN-γ的内在反应来破坏免疫治疗反应。

Zhuang, Wei-Tao; Pang, Lan-Lan; Hu, Li-Yang; Liao, Jun; Zhan, Jian-Hua; Li, Ting; Chen, Ri-Xin; Zheng, Jia-Ni; Li, An-Lin; Yu, Wen-Yan; Mao, Tian-Qin; Chen, Liang; Huang, Yu-Jian; Hong, Shao-Dong; Li, Jing; Wu, Jun-Han; Zeng, Yi-Ming; Yang, Meng-Juan; Zeng, Hai-Qing; Zhang, Ya-Xiong; Zhang, Li; Fang, Wen-Feng

Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial

抗LAG-3抗体LBL-007联合抗PD-1抗体特瑞普利单抗治疗晚期鼻咽癌及其他实体瘤:一项开放标签、多中心、Ib/II期试验

Chen, Gang; Sun, Dong-Chen; Ba, Yi; Zhang, Ya-Xiong; Zhou, Ting; Zhao, Yuan-Yuan; Zhao, Hong-Yun; Fang, Wen-Feng; Huang, Yan; Wang, Zhen; Deng, Chao; Hu, De-Sheng; Wang, Wei; Lin, Jin-Guan; Li, Gui-Ling; Luo, Su-Xia; Fu, Zhi-Chao; Zhu, Hai-Sheng; Wang, Hui-Li; Cai, Sheng-Li; Kang, Xiao-Qiang; Zhang, Li; Yang, Yun-Peng

Correction: Cheng et al. NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. Biomedicines 2022, 10, 2362

更正:Cheng 等人,《NICEFIT——台湾一项前瞻性、非干预性、多中心研究,旨在探讨抗纤维化疗法在特发性肺纤维化管理中的应用》,《生物医学》2022, 10, 2362

Cheng, Shih-Lung; Sheu, Chau-Chyun; Chian, Chih-Feng; Hsu, Jeng-Yuan; Kao, Kuo-Chin; Hang, Liang-Wen; Lin, Ching-Hsiung; Fang, Wen-Feng; Wang, Hao-Chien; Perng, Diahn-Warng

The Mechanical Power in Patients with Acute Respiratory Distress Syndrome Undergoing Prone Positioning Can Predict Mortality

俯卧位通气治疗急性呼吸窘迫综合征患者的机械功率可以预测死亡率

Chang, Ko-Wei; Leu, Shaw-Woei; Hu, Han-Chung; Chan, Ming-Cheng; Liang, Shinn-Jye; Yang, Kuang-Yao; Chiu, Li-Chung; Fang, Wen-Feng; Sheu, Chau-Chyun; Chien, Ying-Chun; Peng, Chung-Kan; Huang, Ching-Tzu; Kao, Kuo-Chin

Leptin and Iinterlukin-6 relationship and influence of mortality in sepsis

瘦素和白细胞介素-6的关系及其对脓毒症死亡率的影响

Tsai, Yi-Hsuan; Hung, Kai-Yin; Fang, Wen-Feng

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

吉非替尼(一种 EGFR 酪氨酸激酶抑制剂)联合安罗替尼(一种多激酶抑制剂)治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌(FL-ALTER):一项多中心 III 期试验

Zhou, Hua-Qiang; Zhang, Ya-Xiong; Chen, Gang; Yu, Qi-Tao; Zhang, Hua; Wu, Guo-Wu; Wu, Di; Lin, Ying-Cheng; Zhu, Jun-Fei; Chen, Jian-Hua; Hu, Xiao-Hua; Lan, Bin; Zhou, Ze-Qiang; Lin, Hai-Feng; Wang, Zi-Bing; Lei, Xiao-Lin; Pan, Suo-Ming; Chen, Li-Ming; Zhang, Jian; Kong, Tian-Dong; Yao, Ji-Cheng; Zheng, Xin; Li, Feng; Zhang, Li; Fang, Wen-Feng

Prognostic evaluation of quick sequential organ failure assessment score in ICU patients with sepsis across different income settings

不同收入水平下重症监护室脓毒症患者快速序贯器官衰竭评估评分的预后评估

Li, Andrew; Ling, Lowell; Qin, Hanyu; Arabi, Yaseen M; Myatra, Sheila Nainan; Egi, Moritoki; Kim, Je Hyeong; Nor, Mohd Basri Mat; Son, Do Ngoc; Fang, Wen-Feng; Wahyuprajitno, Bambang; Hashmi, Madiha; Faruq, Mohammad Omar; Patjanasoontorn, Boonsong; Al Bahrani, Maher Jaffer; Shrestha, Babu Raja; Shrestha, Ujma; Nafees, Khalid Mahmood Khan; Sann, Kyi Kyi; Palo, Jose Emmanuel M; Mendsaikhan, Naranpurev; Konkayev, Aidos; Detleuxay, Khamsay; Chan, Yiong Huak; Du, Bin; Divatia, Jigeeshu Vasishtha; Koh, Younsuck; Phua, Jason

Critical care bed capacity in Asian countries and regions before and during the COVID-19 pandemic: an observational study

新冠疫情前后亚洲国家和地区重症监护床位容量:一项观察性研究

Phua, Jason; Kulkarni, Atul Prabhakar; Mizota, Toshiyuki; Hashemian, Seyed Mohammad Reza; Lee, Won-Yeon; Permpikul, Chairat; Chittawatanarat, Kaweesak; Nitikaroon, Phongsak; Arabi, Yaseen M; Fang, Wen-Feng; Konkayev, Aidos; Hashmi, Madiha; Palo, Jose Emmanuel; Faruq, Mohammad Omar; Shrestha, Babu Raja; Kc, Bijay; Mat Nor, Mohd Basri Bin; Sann, Kyi Kyi; Ling, Lowell; Haniffa, Rashan; Al Bahrani, Maher; Mendsaikhan, Naranpurev; Chan, Yiong Huak

Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation

根据脑转移情况选择EGFR-TKI治疗伴有EGFR p.L861Q突变的晚期非小细胞肺癌。

Pang, Lan-Lan; Zhuang, Wei-Tao; Li, Jun-Jun; Li, Bing; Huang, Yi-Hua; Liao, Jun; Li, Meng-Di; Zhang, Li; Fang, Wen-Feng

Outcomes of combined mitochondria and mesenchymal stem cells-derived exosome therapy in rat acute respiratory distress syndrome and sepsis

线粒体和间充质干细胞来源的外泌体联合疗法治疗大鼠急性呼吸窘迫综合征和脓毒症的疗效

Lin, Kun-Chen; Fang, Wen-Feng; Yeh, Jui-Ning; Chiang, John Y; Chiang, Hsin-Ju; Shao, Pei-Lin; Sung, Pei-Hsun; Yip, Hon-Kan